author-photo

Lucille Ferrante

Janssen Pharmaceutica

8

Papers

40

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

2019 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (33)
PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PF383

2019
Show All
- Source
- Cite
- Save
Citations (1)
To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma

2019 Journal of Oncology Pharmacy Practice
Show All
- Source
- Cite
- Save
Citations (0)
Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

2018 Blood
Show All
- Source
- Cite
- Save
Citations (3)
A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

2017 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (1)